Elan and German firm Boehringer Ingelheim have agreed a global technical development and manufacturing agreement for antibody-based therapeutics.

Under the terms of the deal, Boehringer Ingelheim will perform the technical development, clinical manufacturing and all related regulatory filing support services for antibodies discovered by Elan.

Elan will lead the discovery science, pre-clinical activities, clinical development and commercialisation of such antibodies.

'The agreement enables Elan to focus resources on discovery and the clinical progression of our science while leveraging Boehringer Ingelheim's process development and production capabilities,' the company said.